Bioscience

Biozona Weekly: SFAz economic impact; ASU algae-research leaders; C-Path federal funding

July 19, 2012

By Flinn Foundation

S. AZ’s science synergy
07/15/2012 | Arizona Daily Star | David Wichner

Five years after its inception and nearly three years after losing most of its state funding, Arizona’s public-private science partnership is still bearing fruit – particularly in Southern Arizona.

Study: Science grants aid Arizona economy, education
07/13/2012 | Arizona Republic | Ken Alltucker

Science Foundation Arizona no longer receives funding from the state of Arizona to issue new research and education grants in Arizona, but the group issued a new report today that showed its programs still contribute to Arizona’s economy and science education.

Science Foundation Arizona grants create 1,776 jobs
07/13/2012 | Phoenix Business Journal | Patrick O’Grady

Science Foundation Arizona continues to pump millions of dollars into various technology projects, even as the amount of state money the group receives remains in flux.

2 scientists cited as leaders in quest for fuel from algae
07/11/2012 | Arizona Daily Star | Tom Beal

ASU’s Milton Sommerfeld and Qiang Hu were researching algae long before it came into vogue as a potential replacement for fossil fuel, but they’ve recently been recognized as leaders in the quest.

$10 million in grants to TGen will target brain cancer
07/10/2012 | Arizona Republic | Ken Alltucker

A local brain-cancer foundation’s $10 million in grants to TGen started with a question: Why do 2 percent of people with an aggressive type of brain cancer defy the odds and live much longer than others?

Tucson’s C-Path drug institute looks to boost its future funding
07/10/2012 | Arizona Daily Star | David Wichner

Tucson’s Critical Path Institute recently got some good news – and some noteworthy recognition – when the U.S. Senate gave final approval to a budget reauthorization bill including the Food and Drug Administration partnership program that helps fund the institute.

A New Treatment’s Tantalizing Promise Brings Heartbreaking Ups and Downs
07/08/2012 | The New York Times | Gina Kolata

The second installment in a three-part series on new approaches to fighting cancer explores a patient’s battle with lymphoma, including genetic sequencing at TGen.

Gallagher attorneys aid biotech company in Canadian deals

07/06/2012 | Phoenix Business Journal | Mike Sunnucks

A quartet of Gallagher & Kennedy PA attorneys recently helped an Arizona biotechnology company with a stock offering and other financial deals on the Toronto Stock Exchange.